semaglutide compound shortage Novo Nordisk's officially concludes in the US, spelling major threat for weight loss drug compounders The Semaglutide Shortage Is Ending:

Instead, it uses recognizable food molecules to activate your bodys natural pathwaystriggering not just GLP-1, but an entire symphony of satiety hormones that your body was designed to produce

Key facts: Medicaid launch : as early as May 2026 Participation : voluntary for states states must opt in Pricing : CMS negotiates directly with Eli Lilly (Zepbound/Mounjaro) and Novo Nordisk (Wegovy/Ozempic)

It didn't even happen in a year for me

I could think straight again

Treatment adherence is improving: persistence improved from ~40% for those starting treatment in 2023 to 63% for those beginning in early 2024 (one-year continuation)